JP2022540917A - 治療的処置のためのガボキサドール含有医薬製剤 - Google Patents

治療的処置のためのガボキサドール含有医薬製剤 Download PDF

Info

Publication number
JP2022540917A
JP2022540917A JP2022502537A JP2022502537A JP2022540917A JP 2022540917 A JP2022540917 A JP 2022540917A JP 2022502537 A JP2022502537 A JP 2022502537A JP 2022502537 A JP2022502537 A JP 2022502537A JP 2022540917 A JP2022540917 A JP 2022540917A
Authority
JP
Japan
Prior art keywords
gaboxadol
pharmaceutically acceptable
acceptable salt
pharmaceutical formulation
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540917A5 (enExample
Inventor
デューリング，マシュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2022540917A publication Critical patent/JP2022540917A/ja
Publication of JP2022540917A5 publication Critical patent/JP2022540917A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022502537A 2019-07-15 2020-07-15 治療的処置のためのガボキサドール含有医薬製剤 Pending JP2022540917A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874152P 2019-07-15 2019-07-15
US62/874,152 2019-07-15
PCT/US2020/042044 WO2021011597A1 (en) 2019-07-15 2020-07-15 Pharmaceutical formulations containing gaboxadol for therapeutic treatment

Publications (2)

Publication Number Publication Date
JP2022540917A true JP2022540917A (ja) 2022-09-20
JP2022540917A5 JP2022540917A5 (enExample) 2023-07-26

Family

ID=74211193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502537A Pending JP2022540917A (ja) 2019-07-15 2020-07-15 治療的処置のためのガボキサドール含有医薬製剤

Country Status (10)

Country Link
US (3) US20210015760A1 (enExample)
EP (1) EP3982937A4 (enExample)
JP (1) JP2022540917A (enExample)
KR (1) KR20220035195A (enExample)
CN (2) CN118141810A (enExample)
AU (1) AU2020313930A1 (enExample)
CA (1) CA3146737A1 (enExample)
IL (1) IL289657A (enExample)
MX (1) MX2022000663A (enExample)
WO (1) WO2021011597A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017516868A (ja) * 2014-06-06 2017-06-22 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 持続性抑制を増加させ、二次性不眠症を治療する方法
WO2018031748A1 (en) * 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
WO2018098111A1 (en) * 2016-11-22 2018-05-31 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
JP2018520189A (ja) * 2015-07-17 2018-07-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ガボキサドールでの発達障害の処置方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3154979B1 (en) * 2014-06-12 2018-03-07 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017516868A (ja) * 2014-06-06 2017-06-22 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 持続性抑制を増加させ、二次性不眠症を治療する方法
JP2018520189A (ja) * 2015-07-17 2018-07-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ガボキサドールでの発達障害の処置方法
WO2018031748A1 (en) * 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
WO2018098111A1 (en) * 2016-11-22 2018-05-31 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRONTIERS IN CELLULAR NEUROSCIENCE, vol. 8, no. 119, JPN6024024271, 2014, pages 1 - 23, ISSN: 0005512400 *
TREMOR AND OTHER HYPERKINETIC MOVEMENTS, vol. 8, no. 546, JPN6024024270, 2018, pages 1 - 6, ISSN: 0005512401 *
薬剤学, vol. 70, no. 6, JPN6024024272, 2010, pages 295 - 302, ISSN: 0005512399 *

Also Published As

Publication number Publication date
US20210015760A1 (en) 2021-01-21
IL289657A (en) 2022-03-01
EP3982937A1 (en) 2022-04-20
KR20220035195A (ko) 2022-03-21
CN118141810A (zh) 2024-06-07
CA3146737A1 (en) 2021-01-21
AU2020313930A1 (en) 2022-02-03
MX2022000663A (es) 2022-02-16
US20240252447A1 (en) 2024-08-01
EP3982937A4 (en) 2022-08-10
US20220040120A1 (en) 2022-02-10
CN114173765A (zh) 2022-03-11
WO2021011597A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
JP7801518B2 (ja) 新規な組成物および医薬組成物
EP2688557B1 (en) Methods and compositions for treatment of attention deficit disorder
JPH11511162A (ja) ドーパミン作用物質のための経口速溶性組成物
JP2011515485A (ja) ロフェキシジンを経粘膜送達するための組成物およびその方法
US20200222372A1 (en) Use of gaboxadol in the treatment of narcolepsy
JP2008540437A (ja) キニーネを含有する制御放出調合剤
CN109152841A (zh) N-炔丙胺衍生物的药物组合物
US20240252447A1 (en) Pharmaceutical formulations containing gaboxadol for therapeutic treatment
AU2018285927B2 (en) Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
JP2022511673A (ja) 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用
US11364228B2 (en) Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
KR101473998B1 (ko) 에페리손 함유 필름코팅정제
KR101565505B1 (ko) 에페리손을 함유하는 새로운 약물 전달 시스템
CN113423399A (zh) 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
HK40031715A (en) Use of gaboxadol in the treatment of narcolepsy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250128